Aim: to verify if after the acute phase of ACS acute coronary syndrome (1-months), from 1 to
12 months the reduction of maintenance dose of prasugrel from 10 mg to 5 mg/day may reduce
the bleeding events (5 mg vs 10 mg). All patients will be treated with 325 mg of aspirin
followed by a maintenance dosage of 100 mg of aspirin for at least 1 year. At baseline (after
60 mg loading dose of prasugrel) and after 1 month (7 days after the randomization at 10 or 5
mg of prasugrel) all patients will undergo light transmittance aggregometry (LTA) test to
evaluate residual platelet reactivity (pharmacodynamic effects).